Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · September 23, 2024

Histologic Outcomes of Treatment With Mirikizumab and Their Association With Endoscopic Outcomes in Patients With Crohn's Disease

Clinical Gastroenterology and Hepatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Gastroenterology and Hepatology
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial
Clin. Gastroenterol. Hepatol. 2024 Sep 01;22(9)1878-1888.e10, F Magro, M Protic, G De Hertogh, LS Chan, P Pollack, V Jairath, H Carlier, E Hon, BG Feagan, N Harpaz, R Pai, W Reinisch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading